Published on: December 20, 2024
Views:
--
Discover the OVA Stable Cell Line Model in Just Three Minutes!
Chicken ovalbumin (OVA) is an immunogen commonly used to enhance immune responses. In the fields of immunology and tumor research, OVA stable cell lines are easily recognized by the immune system as non-self cells. They simulate immune responses under specific antigen stimulation, providing critical foundational data and theoretical support for researchers to analyze immune mechanisms and explore disease prevention and treatment methods.
How Are OVA Stable Cell Line Models Constructed?
OVA stable cell line models are typically constructed by cloning the OVA gene sequence into recombinant vectors. Using lentiviral systems or transposon systems, the target sequence is integrated into the host cell chromosome to achieve continuous and stable regulation of the target gene. The mixed cell pool containing positive cells obtained after antibiotic selection are the polyclonal cell pools. While the monoclonal cell lines are derived from polyclonal pools, and are established from the expansion of single cells. Techniques such as RT-qPCR and Western Blot are used to validate OVA protein expression in these stable cell lines, determining their overexpression efficiency and suitability for subsequent in vivo and in vitro experiments.
Widely used OVA stable cell models in scientific research include: B16-OVA, LLC-OVA, EG7-OVA, MC38-OVA, etc.
Applications of OVA Stable Cell Lines
1. Activation of Tumor-Specific Immune Responses
In tumor specific immune research, OVA stable cells are commonly used to study immune responses such as T-cell activation, expansion, and cytotoxicity, especially in response to CD8+ T cells. This cell model helps in understanding how the immune system monitors and attacks tumor cells, as well as how to enhance anti-tumor efficacy through immunotherapy strategies.
Peng et al. constructed a tumor bearing mouse model using EG7-OVA cells and studied the cell and anti-tumor immune response of C6-SPE, C10-SPE, and C16-SPE groups. Research has shown that by regulating the antigen release kinetics of C10-SPE, synergistic cross presentation and co-stimulation effects are achieved, leading to dendritic cells (DCs) homing to draining lymph nodes (dLNs) and generating strong activation. Subsequently, CD8+T cells are functionally and non apoptotic activated, ultimately leading to effective tumor regression.
Figure 1: Anti-tumor immune responses in C6-SPE, C10-SPE, and C16-SPE cell groups.
2. Development of Vaccines and Immunotherapy
The T-cell response activated by OVA can serve as the basis for developing novel vaccines or immunotherapy strategies. By stimulating mice to produce immune responses against OVA, long-term immune memory can be induced, providing protection against tumor cells exposed to OVA again. Zhang et al. further validated the specific anti-tumor immune effects induced by PolyGu NVs by studying their therapeutic effects on a tumor bearing mouse model expressing the model antigen OVA (B16-OVA).
Figure 2. The inhibitory effect of PolyGu NVs on tumor growth.
3. Study Aging and Tumor Immunity
By using tumor cell models expressing OVA, we can also study the changes in the immune system during the aging process, especially its role in tumor immunity. This helps to understand how the immune system declines with age and how immunotherapy strategies can improve cancer treatment outcomes in older adults. The study by Debattama R Sen et al. implanted stable B16-OVA and LLC-OVA cell models into C57BL/6J mice of different ages to investigate the relationship between tumor increase and CD8+T cell infiltration and function during aging.
Figure 3. Aging promotes tumor growth, alters the fate and effector function of CD8+T cells.
Conclusion
The OVA stable cell line model is a powerful and versatile research tool. It offers a robust platform for investigating immune responses to tumors, developing novel vaccines and immunotherapy strategies, and deepening our understanding of aging and tumor immunity mechanisms.
Ubigene’s gga-OVAL lentivirus products are now available, and more OVA stable cell lines, along with other stable cell lines, will be launched soon. Stay tuned!
References:
[1]Spatiotemporal coordination of antigen presentation and co-stimulatory signal for enhanced anti-tumor vaccination. DOI: 10.1016/j.jconrel.2024.08.025
[2]Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy. DOI: 10.1021/acsnano.3c11637
[3]The aged tumor microenvironment limits T cell control of cancer. DOI: 10.1038/s41590-024-01828-7
